MedTrace Logo

Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer

NCT05430009 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-08-01

No results posted yet for this study

Summary

Determine the feasibility of liver stereotactic body radiation therapy (SBRT) given in combination with systemic therapy (immune checkpoint inhibitors) in adult patients with metastatic NSCLC with liver metastases.

Conditions

Interventions

RADIATION

Liver SBRT

24-45 Gy delivered in 3-5 fractions to 1-4 lesions.

DRUG

Pembrolizumab

200 mg every 3 weeks or 400 mg every 6 weeks

Sponsors & Collaborators

  • LUNGevity Foundation

    collaborator OTHER

  • VA Ann Arbor Healthcare System

    lead FED

Principal Investigators

  • Michael Green, MD · VA Ann Arbor

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-17
Primary Completion
2025-12-15
Completion
2026-06-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05430009 on ClinicalTrials.gov